HRP20130171T1 - Farmaceutska formulacija za lijeäśenje gornjeg probavnog sustava - Google Patents

Farmaceutska formulacija za lijeäśenje gornjeg probavnog sustava Download PDF

Info

Publication number
HRP20130171T1
HRP20130171T1 HRP20130171AT HRP20130171T HRP20130171T1 HR P20130171 T1 HRP20130171 T1 HR P20130171T1 HR P20130171A T HRP20130171A T HR P20130171AT HR P20130171 T HRP20130171 T HR P20130171T HR P20130171 T1 HRP20130171 T1 HR P20130171T1
Authority
HR
Croatia
Prior art keywords
effervescent tablet
intended
accordance
digestive system
upper digestive
Prior art date
Application number
HRP20130171AT
Other languages
English (en)
Croatian (hr)
Inventor
Rudolf Wilhelm
Markus PRÖLS
Original Assignee
Dr. Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39951664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130171(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr. Falk Pharma Gmbh filed Critical Dr. Falk Pharma Gmbh
Publication of HRP20130171T1 publication Critical patent/HRP20130171T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20130171AT 2008-07-21 2009-07-02 Farmaceutska formulacija za lijeäśenje gornjeg probavnog sustava HRP20130171T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08013091A EP2151235B1 (de) 2008-07-21 2008-07-21 Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes
PCT/EP2009/058320 WO2010009961A1 (de) 2008-07-21 2009-07-02 Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes

Publications (1)

Publication Number Publication Date
HRP20130171T1 true HRP20130171T1 (hr) 2013-03-31

Family

ID=39951664

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20130171AT HRP20130171T1 (hr) 2008-07-21 2009-07-02 Farmaceutska formulacija za lijeäśenje gornjeg probavnog sustava
HR20110208T HRP20110208T1 (hr) 2008-07-21 2011-03-23 Farmaceutska formulacija za liječenje gornjeg probavnog sustava

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20110208T HRP20110208T1 (hr) 2008-07-21 2011-03-23 Farmaceutska formulacija za liječenje gornjeg probavnog sustava

Country Status (23)

Country Link
US (2) US8580300B2 (enExample)
EP (2) EP2151235B1 (enExample)
JP (2) JP5616889B2 (enExample)
CN (1) CN102159196B (enExample)
AT (1) ATE498396T1 (enExample)
AU (1) AU2009273361B2 (enExample)
CA (1) CA2731312C (enExample)
CY (2) CY1111878T1 (enExample)
DE (1) DE502008002621D1 (enExample)
DK (2) DK2151235T3 (enExample)
EA (1) EA018465B1 (enExample)
ES (2) ES2358158T3 (enExample)
HR (2) HRP20130171T1 (enExample)
IL (1) IL210779A (enExample)
ME (2) ME01256B (enExample)
NZ (1) NZ590593A (enExample)
PL (2) PL2151235T3 (enExample)
PT (2) PT2151235E (enExample)
RS (2) RS51649B (enExample)
SI (2) SI2151235T1 (enExample)
UA (1) UA100759C2 (enExample)
WO (1) WO2010009961A1 (enExample)
ZA (1) ZA201100283B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200562T2 (tr) 1999-06-14 2002-05-21 Cosmo S.P.A Vücutta kontrollü şekilde salgılanabilen ve nahoş tadı önleyebilen ağızdan alınmaya mahsus farmasötik bileşimler
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
ATE498396T1 (de) * 2008-07-21 2011-03-15 Falk Pharma Gmbh Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
HUE040119T2 (hu) 2009-10-01 2019-02-28 Adare Pharmaceuticals Inc Orálisan alkalmazott kortikoszteroid készítmények
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP2886108B2 (de) * 2013-12-23 2022-11-02 Dr. Falk Pharma Gmbh Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807577A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
GB9611364D0 (en) * 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
JP3818789B2 (ja) * 1999-02-18 2006-09-06 三菱化学フーズ株式会社 易崩壊性錠剤
WO2003006629A1 (en) 2001-07-11 2003-01-23 Toshirou Sekine Culturing method and device for photosynthetic microbes
BR0212807A (pt) * 2001-09-25 2004-10-05 Ranbaxy Lab Ltd Processo para a preparação de formas de dosagem de dissolução rápida
JP2005517636A (ja) * 2001-11-20 2005-06-16 ディーエムアイ バイオサイエンシズ インコーポレイテッド オーラル・ケアのための方法および製品
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US20070071817A1 (en) * 2005-09-26 2007-03-29 Phyzz, Inc. Effervescent oral care compositions and method of use
JP2009526858A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー コルチコステロイド溶液を製造する方法
EP2170348B1 (en) * 2007-06-22 2016-08-10 Dompé farmaceutici s.p.a. Effervescent tablets for inhalatory use
EP2205213A2 (en) * 2007-10-01 2010-07-14 Laboratorios Lesvi, S.L. Orodispersible tablets
ATE498396T1 (de) * 2008-07-21 2011-03-15 Falk Pharma Gmbh Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders

Also Published As

Publication number Publication date
NZ590593A (en) 2012-07-27
EA201100229A1 (ru) 2011-08-30
JP5616889B2 (ja) 2014-10-29
AU2009273361A1 (en) 2010-01-28
EP2306988B1 (de) 2013-01-09
ES2399321T3 (es) 2013-03-27
JP2011528679A (ja) 2011-11-24
HRP20110208T1 (hr) 2011-04-30
US20140079646A1 (en) 2014-03-20
RS51649B (sr) 2011-10-31
RS52662B (sr) 2013-06-28
EP2306988A1 (de) 2011-04-13
ME01494B (me) 2014-04-20
PT2151235E (pt) 2011-03-21
HK1149907A1 (en) 2011-10-21
IL210779A (en) 2015-07-30
PT2306988E (pt) 2013-02-15
CY1111878T1 (el) 2015-11-04
ZA201100283B (en) 2011-10-26
WO2010009961A1 (de) 2010-01-28
US20110123460A1 (en) 2011-05-26
SI2151235T1 (sl) 2011-04-29
DK2151235T3 (da) 2011-04-11
EP2151235A1 (de) 2010-02-10
JP2014221827A (ja) 2014-11-27
ATE498396T1 (de) 2011-03-15
CA2731312C (en) 2016-05-10
IL210779A0 (en) 2011-03-31
AU2009273361B2 (en) 2014-03-20
CN102159196B (zh) 2013-05-08
PL2306988T3 (pl) 2013-04-30
CA2731312A1 (en) 2010-01-28
CN102159196A (zh) 2011-08-17
ME01256B (me) 2013-06-20
DE502008002621D1 (de) 2011-03-31
EA018465B1 (ru) 2013-08-30
ES2358158T3 (es) 2011-05-06
US8580300B2 (en) 2013-11-12
EP2151235B1 (de) 2011-02-16
UA100759C2 (uk) 2013-01-25
JP6209495B2 (ja) 2017-10-04
SI2306988T1 (sl) 2013-03-29
CY1113719T1 (el) 2016-06-22
DK2306988T3 (da) 2013-03-18
PL2151235T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
HRP20130171T1 (hr) Farmaceutska formulacija za lijeäśenje gornjeg probavnog sustava
ES2314049T3 (es) Formulaciones liquidas para la prevencion y el tratamiento de enfermedades y trastornos de la mucosa.
ES2539310T3 (es) Composiciones bucosolubles que contienen al menos una sal de S-adenosilmetionina (SAMe)
MX2008000087A (es) Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
BRPI0414311A (pt) formas de dosagem de liberação controlada
PE20050175A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
UA108360C2 (uk) Тверда фармацевтична композиція кортикостероїду, що розпадається у ротовій порожнині
EP2364144A4 (en) GALENIC FORM FOR INSERTION IN THE MOUTH
JP2014221827A5 (enExample)
AR042246A1 (es) Composiciones farmaceuticas que comprenden un compuesto farmacologico basico o acido, un surfactante y un acido o base hidrosoluble fisiologicamente tolerable respectivamente
Singh et al. Review on mucoadhesive drug delivery system with special emphasis on buccal route: an important tool in designing of novel controlled drug delivery system for the effective delivery of pharmaceuticals
JP2007523091A5 (enExample)
CO6160317A2 (es) Formas de dosificacion farmaceutica no manipulables que incluyen un analgesico opioide
JP2010047612A5 (enExample)
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
BR112013006597A2 (pt) tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo
JP2010535767A5 (enExample)
NZ621802A (en) A novel formulation of meloxicam
JP2014500246A5 (enExample)
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
ES2716990T3 (es) Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity